Results 151 to 160 of about 1,701 (184)
Some of the next articles are maybe not open access.
Lenacapavir (Yeztugo) for HIV Pre-Exposure Prophylaxis
The Medical Letter on Drugs and TherapeuticsThe FDA has approved oral and injectable formulations of the HIV-1 capsid inhibitor lenacapavir (Yeztugo – Gilead) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in at-risk adolescents and adults. Lenacapavir is the first drug to be approved for this indication that is given twice-yearly; other drugs approved for this
openaire +2 more sources
Lenacapavir: A Review in HIV Pre-Exposure Prophylaxis
DrugsLenacapavir [YEZTUGO® (USA); YEYTUO® (EU)] is the first twice‑yearly long‑acting injectable option to be approved for HIV pre‑exposure prophylaxis (PrEP). As a potent HIV capsid inhibitor, lenacapavir disrupts multiple stages of the viral replication cycle.
openaire +2 more sources
The road to lenacapavir, a breakthrough HIV treatment
ScienceThree individuals have been awarded the AAAS Mani L.
openaire +1 more source
Lenacapavir: an attractive option, but proceed with caution
The Lancet HIV, 2023openaire +2 more sources
Lenacapavir Ó? a strong weapon to accelerate HIV prevention
Aids ReviewsGlobally, the 2025 prevention target, that is, 95% of people at risk of HIV infection having access to and using effective combination prevention options, is not within reach. Rapid, wider access to pre-exposure prophylaxis (PrEP) could quickly reduce the number of new infections, ultimately among people from key populations.
openaire +2 more sources
Capsid Inhibition With Lenacapavir in Multidrug-Resistant HIV-1 Infection
New England Journal of Medicine, 2022Nicolas A Margot +2 more
exaly
Lenacapavir: a new treatment of resistant HIV-1 infections
The Lancet Infectious Diseases, 2023Ammara, Mushtaq, Farooq, Kazi
openaire +2 more sources